Plafibride: clinical trial of a new platelet antiaggregating agent.
A clinical study with a new anti-aggregant preparation; N-2-(p-chlorophenoxy)-isobutyryl-N'-morpholinomethylurea (plafibride, ITA 104), is shown in this paper. A double blind study, was carried out comparing its effects with those of a well known antiaggregant agent, dipyridamole. No clinical nor analytical side effects of importance were observed.